Significantly higher incidence of skin cancer than other malignancies in patients after heart transplantation. A retrospective cohort study in the Czech Republic

Sečníková, Zuzana; Göpfertová, Dana; Hošková, Lenka; Hercogová, Jana; Džambová, Martina; Jiráková, Anna; Rajská, Lucie; Rob, Filip; Šmerhovský, Zdeněk

doi:10.5507/bp.2015.011

Cited by 12 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Skin cancer is the most common type of malignancy after organ transplantation, 95% of which accounts for NMSC . According to our results, the risk of NMSC, estimated as SMR, appears to be 6.42 times higher compared to the general Czech population, which is comparable to the results of previous retrospective studies conducted in the Czech Republic . The outcomes of foreign population‐based studies prove somewhat higher risk of NMSC with SMR reaching 16.6 in the UK study, 39.2 in Finland, and 56.2 in Swedish population .…”

Section: Discussionsupporting

confidence: 85%

Immunosuppressive therapy in the posttransplant period and skin cancer

Krásová

Sečníková

Göpfertová

et al. 2016

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 85%

Immunosuppressive therapy in the posttransplant period and skin cancer

Krásová

Sečníková

Göpfertová

et al. 2016

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Non-melanoma skin cancers were the most frequent types of malignancy (57.3%), which is in accordance with previous studies ( 4 , 17 ). This consistent finding highlights the importance of cancer screen in HTx patients, especially for the skin cancer.…”

Section: Discussionsupporting

confidence: 92%

Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation

Youn

Kim

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundPost-transplant malignancy (PTM) causes long-term morbidity and mortality in heart transplant (HTx) recipients. However, the detailed characteristics or predictors of PTM are not well-known. We evaluated the incidence, characteristics, long-term outcomes, and predictors of de novo PTM using a single center large-volume database.MethodsWe retrospectively analyzed the types and characteristics of de novo PTM in 989 patients who underwent HTx. Univariate and multivariate logistic regression analyses were used for the PTM prediction model.ResultsTwo hundred and six patients (20.8%) had de novo PTMs (241 cancers) during a median follow-up of 11.5 years. PTM patients were older than non-PTM patients, received immunosuppressive therapy for a longer period, and were more likely to be male and white. Skin cancers were the most frequent types of malignancy (60.6%) followed by prostate (9.5%), lung (7.1%), and breast (4.1%) cancers. Although most cancers (88.8%) were surgically resected at initial presentation, about half (47.3%) recurred or progressed. Patients with skin cancer and non-skin cancer had significantly lower overall survival (P < 0.001) than patients without cancer. Older age (P < 0.001), white race (P = 0.001), and longer time receiving immunosuppressive therapy (P < 0.001) were independent predictors for PTM.ConclusionOlder age, white race, and longer administration of immunosuppressive therapies were independent risk factors for PTM, which was associated with increased mortality. Further research is necessary for the prevention and early detection of PTM in HTx recipients.

show abstract

“…Among viral infections, EBV is the main cause of PTLD. When EBV-seropositive organs have been transplanted to seronegative recipients, these patients are at higher risk of developing PTLD, especially children, who experience primary EBV infection after transplantation [25–27]. In addition to EBV, other viruses such as polyomavirus, cytomegalovirus, and HCV have also been associated with PTLD development in EBV-negative patients [5].…”

Section: Discussionmentioning

confidence: 99%

De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study

et al. 2016

View full text Add to dashboard Cite

Organ transplant recipients appear to have a higher risk of de novo malignancy. The aim of the study was designed to estimate cancer risk in heart, lung, kidney and liver transplant recipients. The cohort study used the Taiwan National Health Insurance Research Database (1996-2011) and followed the outcomes of organ recipients until 2012. De novo cancer and mortality rates after organ transplantation were evaluated using standardized incidence ratios, excess absolute risks of cancer, and standardized mortality ratios in recipients were compared with those in the general population. We identified 40, 231, 2, and 115 patients who developed cancer after heart, kidney, lung, and liver transplantation, which corresponded to a cancer incidence of 878.4, 1101.2, 728.9, and 1361.4 cases per 100,000 person-years, respectively. In heart, kidney, lung, and liver recipients, the overall standardized incidence ratios were 1.65 (1.21-2.24), 3.33 (2.93-3.79), 1.82 (0.45-7.27) and 3.37 (2.81-4.05) and the overall standardized mortality ratios were 5.45 (4.96-5.98), 1.47 (1.34-1.61), 8.92 (7.10-11.20), and 3.83 (3.48-4.20), respectively. These results reveal a three-fold increase in de novo cancer risk in organ transplant patients compared with the general population. This study illustrated the importance of de novo malignancy after organ transplantation.

show abstract

Significantly higher incidence of skin cancer than other malignancies in patients after heart transplantation. A retrospective cohort study in the Czech Republic

Cited by 12 publications

References 14 publications

Immunosuppressive therapy in the posttransplant period and skin cancer

Immunosuppressive therapy in the posttransplant period and skin cancer

Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation

De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study

Contact Info

Product

Resources

About